前列腺癌根治术后持续前列腺特异性抗原升高男性术后放疗的影响:长期生存分析
本研究纳入两家转诊中心1994至2014年间496例根治性前列腺切除术及淋巴结清扫后6-8周PSA持续在0.1-2 ng/ml的患者,建立预测癌症特异性死亡(CSM)的多变量模型。中位随访110个月,49例发生CSM,10年无CSM生存率为88%。术后放疗在预测CSM风险≥30%的患者中与生存获益相关(交互检验p=0.001),而CSM风险<30%者应初始观察等待。
要点
- 病理分级分组和病理分期是CSM的独立预测因素(均p=0.01)。
- 术后6-8周PSA升高仅对基线CSM风险≥10%的患者有预测意义。
- 术后放疗在预测CSM风险≥30%的患者中与生存获益相关(交互检验p=0.001)。
核心结论
- PSA升高应仅作为病理特征较差男性的死亡预测因素。
- 术后放疗在该背景下与CSM风险≥30%患者的生存获益相关,而CSM风险<30%者应初始观察等待。
研究设计与样本
- 回顾性研究,纳入两家转诊中心1994至2014年间496例根治性前列腺切除术及淋巴结清扫后PSA持续(术后6-8周PSA 0.1-2 ng/ml)的患者。
- 建立预测癌症特异性死亡(CSM)的多变量模型,并评估术后PSA水平对生存的影响是否随基线CSM风险而异。
- 采用非参数曲线拟合法探索基线CSM风险与术后放疗后10年CSM率的关系。
主要发现
- 幸存者中位随访110个月,共49例发生CSM,10年无CSM生存率为88%。
- 病理分级分组和病理分期是CSM的独立预测因素(均p=0.01)。
- 无CSM生存与术后6-8周PSA的关联随基线CSM风险而异,PSA升高的效应仅在CSM风险≥10%的患者中明显。
- 术后放疗在预测CSM风险≥30%时有益(交互检验p=0.001)。
关键数值与推荐
- PSA持续定义为根治性前列腺切除术后6-8周PSA水平在0.1-2 ng/ml之间。
- 术后放疗的获益见于预测CSM风险≥30%的患者(交互检验p=0.001)。
- PSA升高的预测效应见于基线CSM风险≥10%的患者。
临床怎么用
- 作者认为,应使用病理特征评估PSA持续患者的CSM风险,并识别可能从术后放疗中获益的患者。
- 作者结论指出,CSM风险≥30%的患者术后放疗与生存获益相关;CSM风险<30%的个体应初始观察等待。
局限性
- 本研究受限于其回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer (PCa) patients with prostate-specific antigen (PSA) persistence after radical prostatectomy (RP) are at increased risk of mortality, although the natural history of these men is heterogeneous and the optimal management has not been established. OBJECTIVE: To develop a model to predict cancer-specific mortality (CSM) and to test the impact of radiotherapy (RT) on survival in this setting. DESIGN, SETTING, AND PARTICIPANTS: We identified 496 patients treated with RP and lymph node dissection at two referral centers between 1994 and 2014 who had PSA persistence, defined as a PSA level between 0.1 and 2 ng/ml at 6-8 wk after RP. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: A multivariable model predicting CSM was developed. We assessed whether the impact of postoperative PSA levels on survival differed according to baseline CSM risk. The nonparametric curve fitting method was then used to explore the relationship between baseline CSM risk and 10-yr CSM rates according to postoperative RT. RESULTS AND LIMITATIONS: Median follow-up for survivors was 110 mo. Overall, 49 patients experienced CSM. The 10-yr CSM-free survival was 88%. Pathologic grade group and pathologic stage were independent predictors of CSM (all p=0.01). The association between CSM-free survival and PSA at 6-8 wk differed by the baseline CSM risk, whereby the effect of increasing PSA was evident only in patients with a CSM risk of ≥10%. Postoperative RT was beneficial when the predicted risk of CSM was ≥30% (p=0.001 by an interaction test). Our study is limited by its retrospective design. CONCLUSIONS: Increasing PSA levels should be considered as predictors of mortality exclusively in men with worse pathologic characteristics. Postoperative RT in this setting was associated with a survival benefit in patients with a CSM risk of ≥30%. Conversely, individuals with a CSM risk of <30% should be initially managed expectantly. PATIENT SUMMARY: Not all patients with prostate-specific antigen persistence have a poor prognosis. Pathologic characteristics should be used to estimate the risk of cancer-specific mortality in these individuals and to identify patients who could benefit from postoperative radiotherapy.
引用
- Gandaglia G, Boorjian SA, Parker WP, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol. 2017. PMID: 28622831. doi:10.1016/j.eururo.2017.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。